Cargando…
Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease
Parkinson’s disease (PD) is a chronic and progressive disorder characterized neuropathologically by loss of dopamine neurons in the substantia nigra, intracellular proteinaceous inclusions, reduction of dopaminergic terminals in the striatum, and increased neuroinflammatory cells. The consequent red...
Autores principales: | Subramaniam, Sudhakar R., Federoff, Howard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463358/ https://www.ncbi.nlm.nih.gov/pubmed/28642697 http://dx.doi.org/10.3389/fnagi.2017.00176 |
Ejemplares similares
-
Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson’s Disease?
por: Janda, Elzbieta, et al.
Publicado: (2018) -
Microglial Activation and Antioxidant Responses Induced by the Parkinson’s Disease Protein α-Synuclein
por: Béraud, Dawn, et al.
Publicado: (2012) -
Pharmacological Targeting of Microglial Activation: New Therapeutic Approach
por: Liu, Cai-Yun, et al.
Publicado: (2019) -
Microglial Turnover in Ageing-Related Neurodegeneration: Therapeutic Avenue to Intervene in Disease Progression
por: Azam, Shofiul, et al.
Publicado: (2021) -
New Therapeutic Avenues of mCSF for Brain Diseases and Injuries
por: Pons, Vincent, et al.
Publicado: (2018)